Risk Factors to Develop Sclerotic Chronic GvHD After Allogeneic HSCT: Preliminary Results of a Multicentre Retrospective study From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
Marie Y. Detrait(Hôpital Civil de Charleroi), Mauricette Michallet(Université Claude Bernard Lyon 1), Didier Blaise(Institut Paoli-Calmettes), Nöel Milpied(Hôpital Cardiologique du Haut-Lévêque), Stéphane Morisset(Lyon 1 Université), Roberto Crocchiolo(Istituti di Ricovero e Cura a Carattere Scientifico), Fiorenza Barraco(Hôpital Lyon Sud), Ibrahim Yakoub‐Agha(Inserm), Nicole Raus, Reza Tabrizi(Université de Bordeaux), Jacques‐Olivier Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Mohamad Sobh(Ottawa Hospital), Régis Peffault de la Tour(Université Paris Cité), Gèrard Socié(Hôpital Saint-Louis), Stéphane Vigouroux(Université de Bordeaux), Mohamad Mohty(Sorbonne Université)
Cited by 0
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859